[Three Cases of Encorafenib Treatment for Recurrent BRAF-Mutated Colorectal Cancer]

Recently, favorable outcomes from encorafenib treatment have been reported in patients with BRAF-mutated colorectal cancer, which has a poor prognosis.

Encorafenib was administered to three patients with recurrence after surgery for BRAF-mutated colorectal cancer. Encorafenib and cetuximab were administered to 2 patients, and encorafenib, binimetinib, and cetuximab were administered to one patient. In all cases, tumor markers decreased, and the metastatic tumors shrank. No severe adverse effects were observed.

BRAF-mutated colorectal cancer often occurs in the right colon. It is also common in older patients, women, and patients with poorly differentiated tumors; our cases exhibited similar characteristics. As previously reported, both doublet and triplet encorafenib treatments are safe and effective.

Combination therapy with encorafenib was effective for the treatment of recurrent BRAF-mutated colorectal cancer, showing good tumor control with few adverse effects. Therefore, this may be a useful treatment option.